Evidence map›Paper›PMID 39499455›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Human herpesvirus 6 (HHV-6) encephalitis secondary to chimeric antigen receptor (CAR)-T cell therapy.

Fahang Yi, Ningxiang Qin, Liang Wang

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fahang YiDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Ningxiang QinDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Liang WangDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. wang0128_0@163.com.ORCID http://orcid.org/0000-0002-0606-561X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman herpesvirus (HHV)-6 encephalitis secondary to chimeric antigen receptor (CAR)-T cell therapyis relatively rare in clinical practice and needs to be differentiated from immune effector cell-associatedneurotoxicity syndrome (ICANS).

methodsWe retrospectively reported a case of HHV-6 encephalitis secondary to CAR-T cell therapy.

resultsA male patient from China with diffuse large B-cell lymphoma underwent chimeric CAR-T cell therapy anddeveloped a generalized rash on the 8

conclusionHHV-6 encephalitis secondary to CAR-T cell therapy may be easily confused with ICANS. Timely andaggressive diagnostic procedures, such as mNGS of CSF and cranial imaging, along with prompt antiviral therapy,are crucial for improving patient outcomes.

Indexed as

Encephalitis, ViralHerpesvirus 6, HumanImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseReceptors, Chimeric AntigenRoseolovirus InfectionsHumansMaleMiddle AgedReceptors, Chimeric AntigenChimeric antigen receptor (CAR)-T cell therapyHematopoietic cell transplantationHuman herpesvirus 6 (HHV-6)LymphomasViral encephalitis

Identifiers

PMID39499455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.